Company news

Share this article:
Schering-Plough ended its partnership with Novacea after its prostate cancer compound Asentar failed in clinical trials. The companies ended a late-stage study of the drug late last year citing an "imbalance" of deaths. Patients taking Asentar died more often than those taking a standard treatment. Asentar rights will be returned to Novacea. Despite the higher-than-expected number of deaths, the company said in published reports it still believes Asentar is a safe drug and called Schering-Plough's decision unexpected.
Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Allergan reported to seek out Salix deal

The Wall Street Journal says the deal would add "another layer of intrigue" to the Allergan-Valeant hostilities.

India's Marck gets FDA Warning Letter

Inspectors of Marck Biosciences found an array of problems during a October-November 2013 inspection, including mold near a sterile area that was so bad "the room had 'partially caved in.'"

DOJ closes Brilinta investigation

AstraZeneca announced the end of the investigation Tuesday.